Icosavax
IPOSeattle, United States · Founded 2018 · $151.0M raised
- Headquarters
- Seattle, Washington
- Founded
- 2018
- Business Model
- B2B
- Website
- icosavax.com
- Total Funding
- $151.0M
- Last Round
- $100.0M Series BApr 2021
- Rounds
- 2
About
Icosavax was a clinical-stage biopharmaceutical company that developed next-generation vaccines using computationally designed virus-like particle (VLP) technology, originally spun out of the University of Washington Institute for Protein Design in 2018. The company's platform enabled the engineering of synthetic nanoparticles that closely mimic natural viruses to elicit potent immune responses, with lead programs targeting RSV and hMPV. Icosavax's VLP-based approach offered a differentiated alternative to mRNA and traditional vaccine modalities. The company was acquired by AstraZeneca in early 2024 for approximately $1.1 billion.
Summary
Icosavax is a Biotech company based in Seattle, United States, founded in 2018. It has raised $151.0M in total across 2 rounds, most recently a $100.0M Series B round in Apr 2021. Investors include Omega Funds, RA Capital Management and Viking Global.
Funding History
Sep 2021
Sign up to see all 4 rounds
Acquisition through IPO — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
China's leading blood products manufacturer
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Specialty pharmaceutical company
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/icosavax"><img src="https://indexed.vc/api/badge/company/icosavax" alt="Icosavax on Indexed.vc" width="260" height="76" /></a>